New '34 Act Onco-R&D-Co To Follow? Minn.'s Celcuity Apparently Bought Its Breast Cancer Candidate From Pfizer For ~$5 Million... Now Stock Up ~620%?

We will likely reserve any judgment on this name for a bit, here. While the Viktoria-1 topline data does look promising, it could be largely due to later stage breast cancer patients hopping into new therapies, when existing ones are not working, for their specific tumor types.

We do note in passing that the cum-laude Harvard educated CEO is making over $6.5 million a year, whilst issuing lots of dilutive new stock to the public, to fund the company -- since it is a pure cash burn, no-revenue shop at the moment. That said, the CEO, Mr. Sullivan, has seen prior successes -- in selling two prior companies he led, to large companies (JNJ and PNG, respectively -- if memory srves), after developing the in-house assets -- and one, even in the life sciences space.

So, in truth it bears. . . watching. The stock price may be a little ahead of itself, given the need to issue more shares -- but in the world of onco-pharma CEOs, $6.5 million a year in pay is about mid-market -- not excessive, at all. . . [and appears positively modest, when one considers that Bitcoin miner (money losing and perennially cash burning) Riot Platforms is paying over $35 million a year to its CEO, Jason Les].

Do your own diligence, but here is an October 2025 run-down on the company's progress, in breast cancers -- and a bit:

. . .Discussing the Viktoria-1 data, Dr. Alessandra Gennari of University of Piemonte Orientale welcomed gedato’s low rates of hyperglycaemia, but pointed to a 69% rate of stomatitis (19% at grade 3+), which is higher than seen with Piqray, Itovebi or Truqap.

Overall, however, this remains a decent result for Celcuity, especially as it had paid just $5m to license gedato from the project’s originator, Pfizer. Now the focus turns to regulatory filing, and data in PIK3CA-mutant cohort breast cancer. . . .

Me?

I might wait a tick(!), to see how the market digests the coming equity dilution -- there may soon be a lower entry-point -- on prices, for a patient set of long term holders, in 2026.

[Onward -- ignoring the latest Trumpian lunacy.]

नमस्ते